Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Next-generation genomic sequencing has identified multiple novel molecular alterations in
cancer. Since the identification of DNA methylation and histone modification, it has become …

Insulin-like growth factors (IGFs) play important roles in mammalian growth, development,
aging, and diseases. Aberrant IGFs signaling may lead to malignant transformation and …

One of the unusual features of germinal center (GC) B cells is that they manifest many
hallmarks of cancer cells. Accordingly, most B‐cell neoplasms originate from the GC …

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and represents
the most common subtype of lymphoma. Although 60–70% of all patients can be cured by …

The enhancer of zeste homolog 2 (EZH2) is encoded by the Enhancer of zeste 2 polycomb
repressive complex 2 subunit gene. EZH2 is involved in the cell cycle, DNA damage repair …

EZH2, the catalytic subunit of PRC2, catalyzes histone H3 lysine 27 (H3K27) trimethylation
to induce the agglutination of chromosomes and in turn represses the transcription of the …

The non-enzymatic functions of target proteins play key roles in the regulation of various cell
signaling pathways and are closely related to numerous human diseases. However …

Enhancer of zeste homolog 2 (EZH2), a catalytic subunit of polycomb repressive complex 2
(PRC2), is overexpressed in triple-negative breast cancer (TNBC), correlating with poor …

Background: Epigenetic mechanisms are critical in the pathogenesis of pulmonary arterial
hypertension (PAH). Previous studies have suggested that hypermethylation of the BMPR2 …